On the occasion of its 20th anniversary, Pharlab, Biogaran’s generics subsidiary in Brazil (for Servier group), has deployed in 2020 major resources to implement the roadmap it has set itself. The inauguration in December of three new sites – R&D laboratory, production unit and distribution center – lays the base for a sustainable future.

Operational since January 2019, the new 630 m² R&D center is resolutely focused on innovation. The expertise of its analytical and galenic laboratories in oral solids (capsules and tablets, ointments and creams) should enable Pharlab to develop new molecules in Brazil, and thus enrich its portfolio. No less than 18 different projects are currently being carried out there, including 8 in the final stages and 10 recently approved.

On the production side, Pharlab has just built a brand new industrial extension of 11,202 m². Equipped with technologies offering a high level of performance and meeting strict quality and safety standards, all its production lines are certified by the regulatory agency Anvisa. In operation since January 2021, this new production unit should enable the Brazilian subsidiary to increase its oral solids production capacity and also to manufacture the new molecules developed by R&D.

Last link in the chain, but not least: logistics. In order to optimize the storage and distribution of its drugs, and thus gain agility, Pharlab decided to bring together all its components (raw materials, packaging, finished products, promotional materials, etc.) at the Lagoa de Prata site, near the plant. Since January 2021, nearly 6,200 pallets have been stored in this new 7,700 m² distribution center.

“Our trust in Pharlab and in the potential of its teams is immense. Thanks to these three new sites, it now has extraordinary know-how and agility, enabling it to quickly bring our products to market for the benefit of South-Americans patients. Pharlab is now paving the way and building the future.”

Pascal Brière, Executive Vice President Generics Activities at Servier